ABBV AbbVie Inc.

NYSE abbvie.com


$ 219.27 $ -0.08 (-0.04 %)    

Friday, 07-Nov-2025 19:43:23 EST
QQQ $ 612.14 $ 1.56 (0.26 %)
DIA $ 470.45 $ 1.64 (0.35 %)
SPY $ 672.31 $ 2.95 (0.44 %)
TLT $ 89.45 $ -0.19 (-0.21 %)
GLD $ 367.77 $ 0.35 (0.1 %)
$ 219.16
$ 219.31
$ 217.34 x 3
$ 219.89 x 1
$ 217.09 - $ 220.99
$ 158.28 - $ 243.06
4,647,894
na
387.34B
$ 0.43
$ 162.20
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-04-2025 09-30-2025 10-Q
2 08-04-2025 06-30-2025 10-Q
3 05-09-2025 03-31-2025 10-Q
4 02-14-2025 12-31-2024 10-K
5 11-04-2024 09-30-2024 10-Q
6 08-07-2024 06-30-2024 10-Q
7 05-03-2024 03-31-2024 10-Q
8 02-20-2024 12-31-2023 10-K
9 11-06-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-05-2023 03-31-2023 10-Q
12 02-17-2023 12-31-2022 10-K
13 11-04-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-06-2022 03-31-2022 10-Q
16 02-18-2022 12-31-2021 10-K
17 11-02-2021 09-30-2021 10-Q
18 08-02-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 02-19-2021 12-31-2020 10-K
21 11-04-2020 09-30-2020 10-Q
22 08-04-2020 06-30-2020 10-Q
23 05-08-2020 03-31-2020 10-Q
24 02-21-2020 12-31-2019 10-K
25 11-06-2019 09-30-2019 10-Q
26 08-05-2019 06-30-2019 10-Q
27 05-03-2019 03-31-2019 10-Q
28 02-27-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-07-2018 06-30-2018 10-Q
31 05-04-2018 03-31-2018 10-Q
32 02-16-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-05-2017 03-31-2017 10-Q
36 02-17-2017 12-31-2016 10-K
37 11-07-2016 09-30-2016 10-Q
38 08-05-2016 06-30-2016 10-Q
39 05-06-2016 03-31-2016 10-Q
40 02-19-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 ubs-maintains-neutral-on-abbvie-raises-price-target-to-220

UBS analyst Ashwani Verma maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $195 to $220.

 piper-sandler-reiterates-overweight-on-abbvie-raises-price-target-to-289

Piper Sandler analyst David Amsellem reiterates AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $284 t...

Core News & Articles

Calico Life Sciences LLC (Calico), a biotechnology organization focused on aging and age-related diseases and founded by Alphab...

 citigroup-maintains-neutral-on-abbvie-lowers-price-target-to-235

Citigroup analyst Geoff Meacham maintains AbbVie (NYSE:ABBV) with a Neutral and lowers the price target from $240 to $235.

 jp-morgan-maintains-overweight-on-abbvie-raises-price-target-to-260

JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $250 to $260.

 nasdaq-100-rebounds-amazon-jumps-10-on-strong-earnings-whats-moving-markets-friday

Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap gi...

 abbvie-raises-2025-outlook-helped-by-strong-immunology-growth-boost-dividend

AbbVie beats Q3 estimates with $15.78 billion revenue, boosts dividend to $1.73, raises earnings outlook on strong drug portfol...

 abbvie-executive-says-administrations-focus-on-achieving-greater-reductions-in-2027-medicare-drug-price-negotiation-round-was-clear-but-outcomes-will-not-impact-long-term-outlook

-Reuters

 abbvie-raises-fy2025-adj-eps-guidance-from-1038-1058-to-1061-1065-vs-1053-est

AbbVie (NYSE:ABBV) raises FY2025 Adj EPS guidance from $10.38-$10.58 to $10.61-$10.65 vs $10.53 analyst estimate..

 abbvie-q3-adj-eps-186-beats-179-estimate-sales-15776b-beat-15590b-estimate

AbbVie (NYSE:ABBV) reported quarterly earnings of $1.86 per share which beat the analyst consensus estimate of $1.79 by 4.09 pe...

 eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash--heres-how-etfs-stand-to-gain

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...

 abbvies-earnings-outlook
AbbVie's Earnings Outlook
10/30/2025 14:02:37

 abbvie-says-canadas-drug-agency-recommends-elahere-be-reimbursed-with-conditions-for-treatment-of-certain-types-of-platinum-resistant-ovarian-cancers

ELAHERE® receives a positive recommendation by Canada's Drug Agency (CDA-AMC)ELAHERE® was submitted for reimbursement revie...

 retail-investors-top-stocks-with-earnings-this-week-sofi-apple-meta-and-more

Investors are gearing up for a jam-packed week of earnings featuring several big tech names and retail-trader favorites. 

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION